Organigram Global Inc. (TSX:OGI)
1.510
+0.030 (2.03%)
Jun 8, 2026, 3:59 PM EST
Organigram Global Revenue
Organigram Global had revenue of 59.79M CAD in the quarter ending March 31, 2026, a decrease of -8.85%. This brings the company's revenue in the last twelve months to 274.19M, up 41.27% year-over-year. In the fiscal year ending September 30, 2025, Organigram Global had annual revenue of 259.18M with 62.15% growth.
Revenue (ttm)
274.19M
Revenue Growth
+41.27%
P/S Ratio
0.77
Revenue / Employee
241.15K
Employees
1,137
Market Cap
212.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 259.18M | 99.34M | 62.15% |
| Sep 30, 2024 | 159.84M | -1.80M | -1.11% |
| Sep 30, 2023 | 161.64M | 15.83M | 10.86% |
| Aug 31, 2022 | 145.81M | 66.65M | 84.19% |
| Aug 31, 2021 | 79.16M | -7.63M | -8.79% |
| Aug 31, 2020 | 86.80M | 6.38M | 7.94% |
| Aug 31, 2019 | 80.41M | 67.98M | 546.98% |
| Aug 31, 2018 | 12.43M | -377.00K | -2.94% |
| Aug 31, 2017 | 12.81M | 550.80K | 4.49% |
| Aug 31, 2016 | 12.26M | 11.27M | 1,142.07% |
| Aug 31, 2015 | 986.68K | - | - |
| Feb 28, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ascend Wellness Holdings | 686.36M |
| Aurora Cannabis | 373.12M |
| TerrAscend | 365.43M |
| Auxly Cannabis Group | 158.57M |
| Medexus Pharmaceuticals | 136.34M |
| Cannara Biotech | 113.01M |
| HLS Therapeutics | 77.81M |
| Cipher Pharmaceuticals | 71.10M |
Organigram Global News
- 27 days ago - Organigram Global Q2 Earnings Call Highlights - MarketBeat
- 27 days ago - Organigram Global Earnings Call Transcript: Q2 2026 - Transcripts
- 27 days ago - Organigram Global Earnings release: Q2 2026 - Filings
- 27 days ago - Organigram Global Registration statement: Q2 2026 - Filings
- 27 days ago - Organigram Global Registration statement: Q2 2026 - Filings
- 27 days ago - Organigram Global Slides: Q2 2026 - Filings
- 27 days ago - OGI Reports Q2 Financials with Adjusted EBITDA Decline - GuruFocus
- 27 days ago - OGI Forecasts Strong FY26 Adjusted EBITDA and Low Capital Expenditures - GuruFocus